Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - UBM, Marinomed, CA Immo (25/08/2021)

29.08.2021

UBM: Real estate developer UBM generated Total Output of Euro 237.3 mn in the first half of 2021, compared with Euro 181.3 mn in the comparable prior year period. EBT declined year-on-year to Euro 35.7 mn (H1/2020: Euro 43.8 mn), but UBM recorded the highest net profit in its history at Euro 27.5 mn (H1/2020: Euro 26.6 mn). The sound first half-year results and sales activity expected over the coming months make it possible for UBM to issue a guidance for the 2021 financial year: “Instead of the previously announced “corona dip”, we now expect an EBT of Euro 55 mn to Euro 60 mn” says UBM CEO Thomas G. Winkler “and with the sale of several projects prior to the start of construction, we successfully steered through these challenging times.”
UBM: weekly performance: 4.22%

Marinomed: Due to strong demand in Marinomed’s Carragelose-based virus blockers, revenues of the Company increased by 41% to Euro 3.2 mn (H1 2020: Euro 2.3 mn), supported by positive scientific and clinical data on the anti-SARS-CoV-2 activity of Carragelose-based products. Due to increased R&D expenses of Euro 4.3 mn (H1 2020: Euro 2.2 mn) for the two technology platforms, Carragelose and Marinosolv, the operating result (EBIT) decreased to Euro -3.6 mn (H1 2020: Euro -2.9 mn), which is in-line with Marinomed’s business plan. Net loss for the period was Euro 4.4 mn compared to Euro 3.2 mn in H1 2020. “We are pleased about the strong growth in the first half of the year. Carragelose products gained market share in many markets and while pharmacies reported declining sales in the cough and cold segment, sales of Carragelose products increased. However, with the pandemic moving into a more endemic phase, we expect the return of the typical seasonality of sales. Going forward, we plan to further extend our clinical activities and to slightly increase R&D spending compared to 2020. R&D will focus more on Marinosolv again, as this segment has significant untapped potential,” said Pascal Schmidt, CFO of Marinomed.
Marinomed Biotech: weekly performance: -0.45%

CA Immo: Real estate company CA Immo recorded a 1.5% increase in rental income to Euro 119.9 mn in the first six months. This positive development is related to the portfolio growth of the past quarters. FFO I, key indicator for the sustainable earnings power of the Group, which is reported before tax and adjusted for the sales result and other non-sustainable effects, stood at Euro 68.5 mn (30.6.2020: Euro 68.2 mn). CA Immo had an almost complete external valuation of the portfolio carried out as at 30 June 2021. The result is a significantly higher revaluation result of Euro 195.3 mn compared to the previous year (30.6.2020: Euro –27.0 mn). The consolidated net profit of Euro 171.3 mn was substantially higher than the previous year's figure of Euro 44.7 mn.
CA Immo: weekly performance: -0.14%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/08/2021)


Partners









latest 21st Austria

21st Austria weekly - UBM, Marinomed, CA Immo (25/08/2021)


29.08.2021, 2943 Zeichen



UBM: Real estate developer UBM generated Total Output of Euro 237.3 mn in the first half of 2021, compared with Euro 181.3 mn in the comparable prior year period. EBT declined year-on-year to Euro 35.7 mn (H1/2020: Euro 43.8 mn), but UBM recorded the highest net profit in its history at Euro 27.5 mn (H1/2020: Euro 26.6 mn). The sound first half-year results and sales activity expected over the coming months make it possible for UBM to issue a guidance for the 2021 financial year: “Instead of the previously announced “corona dip”, we now expect an EBT of Euro 55 mn to Euro 60 mn” says UBM CEO Thomas G. Winkler “and with the sale of several projects prior to the start of construction, we successfully steered through these challenging times.”
UBM: weekly performance: 4.22%

Marinomed: Due to strong demand in Marinomed’s Carragelose-based virus blockers, revenues of the Company increased by 41% to Euro 3.2 mn (H1 2020: Euro 2.3 mn), supported by positive scientific and clinical data on the anti-SARS-CoV-2 activity of Carragelose-based products. Due to increased R&D expenses of Euro 4.3 mn (H1 2020: Euro 2.2 mn) for the two technology platforms, Carragelose and Marinosolv, the operating result (EBIT) decreased to Euro -3.6 mn (H1 2020: Euro -2.9 mn), which is in-line with Marinomed’s business plan. Net loss for the period was Euro 4.4 mn compared to Euro 3.2 mn in H1 2020. “We are pleased about the strong growth in the first half of the year. Carragelose products gained market share in many markets and while pharmacies reported declining sales in the cough and cold segment, sales of Carragelose products increased. However, with the pandemic moving into a more endemic phase, we expect the return of the typical seasonality of sales. Going forward, we plan to further extend our clinical activities and to slightly increase R&D spending compared to 2020. R&D will focus more on Marinosolv again, as this segment has significant untapped potential,” said Pascal Schmidt, CFO of Marinomed.
Marinomed Biotech: weekly performance: -0.45%

CA Immo: Real estate company CA Immo recorded a 1.5% increase in rental income to Euro 119.9 mn in the first six months. This positive development is related to the portfolio growth of the past quarters. FFO I, key indicator for the sustainable earnings power of the Group, which is reported before tax and adjusted for the sales result and other non-sustainable effects, stood at Euro 68.5 mn (30.6.2020: Euro 68.2 mn). CA Immo had an almost complete external valuation of the portfolio carried out as at 30 June 2021. The result is a significantly higher revaluation result of Euro 195.3 mn compared to the previous year (30.6.2020: Euro –27.0 mn). The consolidated net profit of Euro 171.3 mn was substantially higher than the previous year's figure of Euro 44.7 mn.
CA Immo: weekly performance: -0.14%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/08/2021)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsenradio Live-Blick, Mi. 28.2.24: Fünfter DAX-Rekord in Folge? Baader Bank sieht 18.000, Zertifikat für Buy the Dip Fans bei RWE




 

Bildnachweis

Aktien auf dem Radar:Porr, Flughafen Wien, UBM, Warimpex, Amag, RHI Magnesita, ams-Osram, Verbund, Österreichische Post, EuroTeleSites AG, FACC, AT&S, Strabag, Cleen Energy, Lenzing, S Immo, BKS Bank Stamm, Zumtobel, Agrana, Addiko Bank, CA Immo, Erste Group, EVN, Immofinanz, Telekom Austria, Uniqa, VIG, Wienerberger, BMW, Porsche Automobil Holding, Deutsche Boerse.


Random Partner

AVENTA AG
Die AVENTA AG ist ein Immobilienunternehmen mit Sitz in Graz, das von den Hauptaktionären Christoph Lerner und Bernhard Schuller geführt wird. Geschäftsschwerpunkt ist die Entwicklung von Wohnimmobilien von der Projektentwicklung über die technische Projektierung bis hin zu den fertigen Objekten.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten